---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-02"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-02. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 81 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence/cdx0159-02"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-02

<a id="heading-3.1.5"></a>

## 3.1.5 CDX0159-02

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Primary objective: safety of multiple doses

> “The main objective of the trial was to evaluate the barzolvolimab MAD safety profile.”
> “Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.1-2"></a>

#### Secondary objectives: pharmacokinetics, disease activity, tryptase, SCF, and immunogenicity

> “The secondary objectives were to characterize the barzolvolimab MAD PK profile; PD effect (UAS7, HSS7, itch severity score [ISS7], and urticaria control test [UCT]); tryptase and SCF levels; and immunogenicity.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.1-3"></a>

#### Registry purpose: safety, pharmacodynamics, and pharmacokinetics in antihistamine-refractory CSU

> “The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registry dates and study sites in the United States and Germany

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2020-09-24” |
| Primary completion (actual) | “2023-01-17” |
| Study completion (actual) | “2023-01-17” |
| Countries of listed sites | “United States”; “Germany” |
| Site in Germany | “Charite University” |

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.2-2"></a>

#### Multicenter study

> “We have completed a Phase 1b randomized, double-blind, placebo-controlled multi-center study of barzolvolimab in CSU.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-3.1.5.2-3"></a>

#### First participant dosed, October 2020

> “HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-3.1.5.2-4"></a>

#### Study completion reported in June 2023

> “HAMPTON, N.J., June 10, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that updated data from the Company’s Phase 1b multi-dose clinical trial in chronic spontaneous urticaria (CSU)”
> “The study is now complete.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

<a id="topic-3.1.5.2-5"></a>

#### Congress presentations of the data in 2023

> “Data from this study were reported across multiple medical meetings, including the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in February 2023, the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in June 2023 and the European Academy of Dermatology & Venereology (EADV) Congress in October 2023.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Randomized, double-blind, placebo-controlled design with screening, treatment, and follow-up periods

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “The study included the following periods: 2‐week screening, 12‐week treatment, and 12‐week posttreatment follow‐up (Figure S1).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-2"></a>

#### Four sequentially enrolled intravenous cohorts randomized 4:1

> “treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo)”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-3"></a>

#### Registry title: phase 1 multiple ascending dose add-on study

> “A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria”
> “There is a screening period of up to 2 weeks, a 12-week double-blind treatment period and a 12-week follow-up period after treatment.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.3-4"></a>

#### Follow-up for 12 weeks or until symptoms resumed

> “Following completion of the 12 week treatment period, patients were followed for an additional 12 weeks or until resumption of symptoms, whichever was sooner.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.3-5"></a>

#### Dose and schedule selection from the single-dose healthy-volunteer study

> “Doses were selected based on results from the single‐dose healthy‐volunteer study [10], in which 0.3–9 mg/kg barzolvolimab was well tolerated and demonstrated dose‐dependent suppression of serum tryptase (Supporting Information Methods).”
> “Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-6"></a>

#### Sponsor role in design, data analysis, and manuscript preparation

> “This trial was designed and sponsored by Celldex Therapeutics.”
> “Data were collected by the trial investigators according to Good Clinical Practice guidelines and were analyzed by the sponsor.”
> “The first draft of the manuscript was written by a medical writer paid by the sponsor, with critical input and approval from all authors.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion criteria: age, disease activity, disease duration, and antihistamine use

> “Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).”
> “Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.”
> “Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.4-2"></a>

#### Exclusion criteria: recent biologics, prior barzolvolimab, immunosuppressives, oral doxepin, and other itching skin disease

> “Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.4-3"></a>

#### Prior biologic treatment permitted with washout

> “This is a randomized, double-blind, placebo-controlled, multiple ascending dose study in adults with moderate-to-severe chronic CSU (weekly urticaria activity score [UAS7] ≥16) refractory to H1 antihistamines; prior treatment with biologics permitted with washout.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.4-4"></a>

#### Registry criteria: blood counts, contraception for 150 days, live vaccines, pregnancy, and anaphylaxis

> “Normal blood counts and liver function tests.”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days afterwards after treatment.”
> “Women who are pregnant or nursing.”
> “Vaccination with a live vaccine within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study).”
> “History of anaphylaxis.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Intravenous infusion every 4 or 8 weeks as add-on to antihistamines

> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.5-2"></a>

#### Number of doses in each cohort

> “Barzolvolimab was administered intravenously at 0.5 mg/kg every 4 weeks (3 doses), 1.5 mg/kg every 4 weeks (3 doses), 3 mg/kg every 8 weeks (2 doses), 4.5 mg/kg every 8 weeks (2 doses), as add-on treatment to H1-antihistamines, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.5-3"></a>

#### Rescue medication

> “Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.5-4"></a>

#### Registry arms: CDX-0159 or normal saline every 4 to 8 weeks

> “CDX-0159 every 4-8 weeks”
> “Normal saline every 4-8 weeks”
> “Administered intravenously”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Incidence of Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Registry primary outcome: incidence and severity of adverse events to Day 169

> “Safety as assessed by the incidence and severity of adverse events”
> “Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events”
> “From Day 1 (first dose) to Day 169 (last follow-up visit)”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.6.1-2"></a>

##### Safety assessments

> “Safety was assessed by the incidence and severity of treatment‐emergent adverse events (TEAEs) and serious AEs (SAEs), dose‐limiting toxicities, clinical laboratory tests, vital sign measurements, 12‐lead electrocardiograms, and physical examinations.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.6.1-3"></a>

##### Rationale: first multiple-dose study after single-dose studies

> “We report the effect of multiple ascending doses (MAD) of barzolvolimab on safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and clinical activity in CSU patients whose disease is inadequately controlled by antihistamines.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Single dose studies have shown that barzolvolimab is generally well tolerated and has significant clinical activity in antihistamine refractory chronic inducible urticaria (CINDU), including biologic refractory, with profound suppression of circulating tryptase and depletion of skin MCs.”
> “Here we report safety and clinical activity data of a Phase 1 multiple-ascending dose trial of barzolvolimab in antihistamine refractory chronic spontaneous urticaria (CSU) patients.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

> “We report results from the first multiple dose study of barzolvolimab in CSU patients.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.6.1-4"></a>

##### Registry secondary outcomes: pharmacokinetics, UAS7, HSS7, ISS7, UCT, stem cell factor, tryptase, and immunogenicity

> “CDX-0159 serum concentrations will be measured at specified visits”
> “The change from baseline for Urticaria Activity Score (UAS7) in patients who received CDX-0159 vs. placebo”
> “The change from baseline for Hives Severity Score (HSS7) in patients who received CDX-0159 vs. placebo”
> “The change from baseline for Itch Severity Score (ISS7) in patients who received CDX-0159 vs. placebo”
> “The change in baseline for Urticaria Control Test (UCT) in patients who received CDX-0159 vs. placebo”
> “The effect of CDX-0159 on stem cell factor levels”
> “The effect of CDX-0159 on tryptase”
> “Assessment of immunogenicity by measuring the development of anti- CDX-0159 antibodies”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.6.1-5"></a>

##### Weekly urticaria activity score (UAS7): components, range 0 to 42, and disease activity categories

> “The UAS7 score is calculated as the sum over 7 days of the daily intensity of itch (ISS7 itch severity score) and number of hives (HSS7 hives severity score). UAS7 values range from 0 to 42, with higher values reflecting higher disease activity.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

> “disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.6.1-6"></a>

##### Urticaria Control Test (UCT): range 0 to 16, complete control at 16, well controlled at 12 or more

> “UCT has 4 items with 5 answer options (scored with 0-4 points); recall period of 4 weeks. Low points indicate high disease activity and low disease control. The minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control and ≥12 indicating well controlled disease.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.6.1-7"></a>

##### Assessment ranges for UAS7, AAS7, UCT, and DLQI

> “Assessments: Safety, 7-day Urticaria Activity Score (UAS7; range 0-42), 7-day Angioedema Activity Score (AAS7; range 0-105), Urticaria Control test (UCT; range 0-16) , Dermatology Life Quality Index (DLQI; range 0-30), circulating Tryptase and Stem Cell Factor (SCF).”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.6.1-8"></a>

##### Physician Global Assessment (PhysGA): range 0 to 3

> “Physician Global Assessment (PhysGA; range 0-3)”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Planned enrollment: approximately 40 participants in four cohorts

> “The study is expected to enroll approximately 40 patients with CSU across four cohorts (8 CDX-0159; 2 placebo).”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-3.1.5.7.1-2"></a>

##### Screened and randomized participants

> “A total of 74 patients were screened, of whom 45 were randomly assigned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.1-3"></a>

##### Participants by cohort

> “0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9)”
> “All barzolvolimab (N = 35)”
> “Pooled placebo (N = 10)”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.1-4"></a>

##### Interim analysis population, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated [26 barzolvolimab (n=9 in 0.5 mg/kg; n=8 in 1.5 mg/kg; n=9 in 3.0 mg/kg) and 8 placebo].”
> “The 0.5 mg/kg and 1.5 mg/kg cohorts had completed study participation through 24 weeks; 7 of 12 patients in the 3.0 mg/kg cohort had completed week 12; enrollment in the 4.5 mg/kg cohort was ongoing.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.7.1-5"></a>

##### Analysis population, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete with 45 patients with moderate to severe CSU refractory to antihistamines enrolled and treated [35 barzolvolimab (n=9 in 0.5 mg/kg; n=8 in 1.5 mg/kg; n=9 in 3.0 mg/kg; n=9 in 4.5 mg/kg) and 10 placebo].”
> “The 0.5 mg/kg, 1.5 mg/kg and 3.0 mg/kg cohorts had completed study participation through 24 weeks; 6 of 9 patients in the 4.5 mg/kg cohort had completed through the week 20 visit.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Safety population: all participants who received at least one dose

> “The analysis population was the safety population, defined as all patients who received at least one dose of study treatment.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-2"></a>

##### Analysis by dose with placebo pooled across cohorts

> “Results were analyzed by dose and overall for patients who received barzolvolimab. The placebo group was pooled from each cohort. Baseline was defined as the last available measurement prior to study treatment administration. Change from baseline was calculated as the difference between postbaseline and baseline values.”
> “Safety was assessed separately by treatment group and as pooled active treatment. Analyses included the number and percentage of patients experiencing AEs, summarized by severity and relationship to study drug.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-3"></a>

##### Descriptive pharmacokinetic, antidrug antibody, and pharmacodynamic analyses

> “PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings. The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively. Summary statistics were descriptive and presented to evaluate PD changes.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-4"></a>

##### Analysis set and data included at the November 2022 data cutoff

> “All data were analyzed by treatment group (placebo patients pooled) for patients who received at least one dose of study treatment. Data cut 29NOV2022”
> “Complete data are included for all patients in dose levels through 3 mg/kg through 24 weeks.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.7.2-5"></a>

##### Company responder analyses: participants with missing data excluded, Week 24 shown only where at least 50% had data

> “Clinical responses shown are the proportion of patients with the defined response at the specific timepoint. Patients with missing data at the timepoint are excluded.”
> “Data for week 24 included only for dose levels with at least 50% of patients with data available at the timepoint; data not shown for 0.5 mg/kg and placebo dose levels as most patients had significant symptoms ahead of week 24 and discontinued follow up.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Completion of the 12-week treatment period

> “Overall, 42 patients (93.3%) completed treatment (Figure S2). Three patients did not complete the treatment period: one in the barzolvolimab 4.5‐mg/kg group because of low white blood count (WBC), and two in the placebo group who sought alternate treatment for CSU because of symptom severity.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.1-2"></a>

##### Doses not received and follow-up discontinuation, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Data for the 0.5 mg/kg and placebo group are only included through week 12 because, as expected, most patients from these groups had significant symptoms ahead of week 24 and discontinued follow up. Two patients did not receive all doses of study treatment [4.5 mg/kg (1), placebo (1)].”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographics and baseline disease characteristics by cohort

| Characteristic | 0.5 mg/kg Q4W (N = 9) | 1.5 mg/kg Q4W (N = 8) | 3.0 mg/kg Q8W (N = 9) | 4.5 mg/kg Q8W (N = 9) | All barzolvolimab (N = 35) | Pooled placebo (N = 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Age, years, mean (range) | “43.8 (21–73)” | “53.3 (29–75)” | “49.4 (26–65)” | “51.1 (29–68)” | “49.3 (21–75)” | “49.8 (18–70)” |
| Female, n (%) | “6 (67)” | “7 (88)” | “6 (67)” | “9 (100)” | “28 (80)” | “7 (70)” |
| BMI, kg/m2, mean (range) | “31.1 (26.0–36.0)” | “37.8 (28.6–58.9)” | “29.4 (22.3–36.9)” | “27.1 (21.5–34.4)” | “31.2 (21.5–58.9)” | “31.8 (16.4–55.2)” |
| CSU duration, years, mean (range) | “7.5 (0.6–41.1)” | “17.1 (2.6–61.3)” | “4.8 (0.6–21.3)” | “10.4 (1.0–35.4)” | “9.7 (0.6–61.3)” | “5.6 (1.4–13.1)” |
| Prior H2-antihistamine, n (%) | “6 (67)” | “4 (50)” | “4 (44)” | “6 (67)” | “20 (57)” | “4 (40)” |
| Prior leukotriene receptor antagonist, n (%) | “3 (33)” | “2 (25)” | “0 (0)” | “3 (33)” | “8 (23)” | “2 (20)” |
| Prior omalizumab, n (%) | “4 (44)” | “3 (38)” | “4 (44)” | “2 (22)” | “13 (37)” | “6 (60)” |
| UAS7, mean (range) | “31.1 (20.0–39.0)” | “29.5 (20.0–40.6)” | “29.4 (16.3–42.0)” | “28.3 (22.0–38.0)” | “29.6 (16.3–42.0)” | “35.8 (19.0–42.0)” |
| AAS7 positive at baseline, n (%) | “5 (56)” | “6 (75)” | “7 (78)” | “8 (89)” | “26 (74)” | “5 (50)” |
| AAS7 in those positive at baseline, mean (range) | “29.0 (4.0–59.5)” | “43.3 (1.0–79.0)” | “29.8 (3.0–49.0)” | “33.7 (6.0–80.0)” | “34 (1.0–80.0)” | “53.2 (3.5–80.5)” |
| UCT, mean (range) | “1.7 (0–4)” | “2.4 (1–8)” | “3.1 (0–7)” | “4.7 (1–12)” | “3.0 (0–12)” | “3.4 (0–11)” |
| Tryptase, ng/mL, mean (range) | “5.0 (2.0–10.3)” | “6.3 (2.8–15.1)” | “8.6 (3.3–28.8)” | “5.5 (2.3–10.2)” | “6.2 (2.0–28.8)” | “5.3 (3.2–7.5)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.2-2"></a>

##### Disease severity, prior omalizumab and biologic use, and angioedema history

> “Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use.”
> “The majority had an inadequate response to omalizumab.”
> “There were no notable differences between the barzolvolimab and placebo groups in the demographic or clinical characteristics at baseline (Table 1). Most patients had severe disease per UAS7. A total of 44% of patients had prior use of biologics. The percentage of patients with a history of angioedema was similar between placebo (50%) and across the barzolvolimab groups (60%), with mean baseline angioedema activity score over 7 days (AAS7) of 26.6 and 26.0, respectively.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.2-3"></a>

##### Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff

> “Data cut 29NOV2022”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Race, White, n (%) | “6 (67)” | “7 (88)” | “9 (100)” | “7 (78)” | “29 (83)” | “7 (70)” |
| Race, African American, n (%) | “3 (33)” | “1 (13)” | “0 (0)” | “1 (11)” | “5 (14)” | “3 (30)” |
| Race, Other, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (11)” | “1 (3)” | “0 (0)” |
| Prior angioedema, n (%) | “5 (56)” | “5 (63)” | “5 (56)” | “6 (67)” | “21 (60)” | “5 (50)” |
| ISS7, mean (range) | “15.7 (11.0 - 21.0)” | “15.5 (12.0 - 21.0)” | “14.6 (1.2 - 21.0)” | “15.4 (10.5 -19.0)” | “15.3 (1.2 - 21.0)” | “19.3 (12.0 - 21.0)” |
| HSS7, mean (range) | “15.4 (8.0 - 21.0)” | “14.0 (8.0 - 21.0)” | “14.8 (8.0 - 21.0)” | “12.4 (7.0 -19.0)” | “14.1 (7.0 - 21.0)” | “16.5 (7.0 - 21.0)” |
| UAS7, mean (range) | “31.1 (20.0 - 39.0)” | “29.4 (20.0 - 40.6)” | “29.4 (16.3 - 42.0)” | “27.8 (17.5 - 38.0)” | “29.4 (16.3 - 42.0)” | “35.8 (19.0 - 42.0)” |
| Total IgE, kU/L, mean (range) | “80 (2 - 239)” | “161 (13 - 328)” | “337 (4 - 1371)” | “88 (2 - 307)” | “165 (2 - 1371)” | “161 (5 - 409)” |

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.2-4"></a>

##### Baseline DLQI and PhysGA by cohort

| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| DLQI, mean (range) | “13.2 (7-24)” | “15.1 (5-24)” | “7.8 (1-15)” | “9.7 (1-16)” | “11.3 (1-24)” | “13.5 (1-26)” |
| PhysGA, mean (range) | “1.9 (1-3)” | “2.3 (1-3)” | “2.7 (2-3)” | “2.1 (1-3)” | “2.2 (1-3)” | “2.1 (1-3)” |

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.8.2-5"></a>

##### Prior omalizumab use in interim company reports, May 2022 and November 2022 data cutoffs

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “42% of patients treated with barzolvolimab had prior omalizumab and had similar symptom improvement as overall population”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “37% of treated patients had prior omalizumab therapy and still had similar clinical benefit improvement as the overall population”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Week 12 UAS7 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6), all barzolvolimab doses versus placebo

> “UAS7 response to barzolvolimab was greater than placebo: 71.4% of barzolvolimab‐treated patients had a well‐controlled response (UAS7 ≤ 6) by Week 12, compared with 30.0% of placebo‐treated patients (Figure 1C), and 57.1% of barzolvolimab‐treated patients had a complete response (UAS7 = 0) by Week 12 compared with 20% of placebo‐treated patients (Figure 1D).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-2"></a>

##### Week 12 UCT well-controlled disease (UCT ≥ 12) and complete response (UCT = 16), all barzolvolimab doses

> “Overall, 77.1% of barzolvolimab‐treated patients achieved a well‐controlled response (UCT ≥ 12), and 42.9% of the patients who received barzolvolimab achieved a complete response (UCT = 16) by Week 12.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-3"></a>

##### UAS7, HSS7, ISS7, and UCT change from baseline from Week 1 through Week 24

> “Urticaria symptoms measured by change from baseline in UAS7 improved by Week 1 (Figure 1A) for all barzolvolimab dose levels compared with placebo. Sustained improvement of UAS7 scores through Week 24 was seen for the groups ≥ 1.5 mg/kg. HSS7 and ISS7, the two components of UAS7 score, showed comparable improvement in each urticaria symptom measurement by Week 1 and sustained improvement of scores through Week 24 for the ≥ 1.5‐mg/kg groups (Figure S4). Sustained improvement was also observed by change from baseline in UCT (Figure 1B).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-4"></a>

##### Week 24 urticaria-free status (UAS7 = 0) at doses of 1.5 mg/kg or more, 16 weeks after the last dose

> “As tryptase levels were suppressed, improvement in UAS7 was observed within 1 week, and > 50% of patients at doses ≥ 1.5 mg/kg remained urticaria free at Week 24, 16 weeks after their last dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-5"></a>

##### Transient response at the lowest dose (0.5 mg/kg)

> “The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-6"></a>

##### Prior omalizumab subgroup: Week 12 UAS7 = 0 and UAS7 ≤ 6, pooled doses of 1.5 mg/kg or more

> “A subgroup analysis of patients who had previously received omalizumab had a similar response profile (UAS7 and UCT) to those who were naive to omalizumab (Figure 3); the majority of experienced patients had discontinued prior omalizumab because of a lack of symptom control. Doses ≥ 1.5 mg/kg were pooled in barzolvolimab‐treated patients, and a complete response (UAS7 = 0) and well‐controlled response (UAS7 ≤ 6) by Week 12 were observed in 53.8% and 84.6% of barzolvolimab‐treated patients with prior omalizumab treatment, respectively, which is similar to the overall group.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Oma Naïve n=17”
> “Oma Experienced n=9”
> “Pooled data from saturating doses (1.5, 3.0 and 4.5 mg/kg)”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-7"></a>

##### Authors' comparison with omalizumab registrational trials at Week 12

> “A total of 71% of barzolvolimab‐treated patients across doses achieved a well‐controlled (UAS7 ≤ 6) response, and 57% of the patients achieved a complete response (UAS7 = 0) during the first 12 weeks (compared with 36% of participants treated with omalizumab 300 mg Q4W in registrational trials at 12 weeks [12]); this was sustained through Week 24.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-8"></a>

##### Pooled doses of 1.5 mg/kg or more: UAS7 = 0 and UAS7 ≤ 6 at Weeks 12 and 24

> “Complete response (Urticaria free) at doses ≥ 1.5 mg/kg:”
> “56% of patients at Week 12”
> “55% of patients at Week 24”
> “Well controlled Urticaria at doses ≥ 1.5 mg/kg:”
> “64% of patients at Week 12”
> “60% of patients at Week 24”
> “Well Controlled Urticaria UAS7 ≤ 6”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-9"></a>

##### Week 12 UAS7 and UCT by cohort, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Mean reduction from baseline in urticaria activity (UAS7) at week 12 of 67% in the 1.5 mg/kg dose group (n=8), 67% in the 3.0 mg/kg dose group (n=9) and 82% in the 4.5 mg/kg dose group (n=9).”
> “Complete response (UAS7=0) at week 12 of 57% in the 1.5 mg/kg dose group, 44% in the 3.0 mg/kg dose group and 67% in the 4.5 mg/kg dose group.”
> “Well-controlled disease (UCT≥ 12) at week 12 of 75% in the 1.5 mg/kg dose group, 63% in the 3.0 mg/kg dose group and 89% in the 4.5 mg/kg dose group.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.8.3-10"></a>

##### Pooled doses of 1.5 mg/kg or more: UAS7 = 0 at Weeks 12 and 20, November 2022 data cutoff

> “Data cut 29NOV2022”
> “56% of patients treated with doses ≥1.5 mg/kg achieved complete response at week 12 and 68% at week 20 with additional follow up ongoing for patients treated with 4.5 mg/kg.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.3-11"></a>

##### Week 24 UAS7 and UCT by cohort, complete 24-week data

> “At EAACI 2023, Celldex presented data on the complete 24 week experience for the 4.5 mg/kg cohort and data on angioedema impact across all study cohorts.”
> “Mean reduction from baseline in urticaria activity (UAS7) at week 24 was 80% in the 1.5 mg/kg dose group (n=7), 70% in the 3.0 mg/kg dose group (n=6) and 77% in the 4.5 mg/kg dose group (n=7).”
> “Complete response (UAS7=0) at week 24 was 57% in the 1.5 mg/kg dose group, 67% in the 3.0 mg/kg dose group and 43% in the 4.5 mg/kg dose group.”
> “Well-controlled disease (UCT≥ 12) at week 24 was 75% in the 1.5 mg/kg dose group, 67% in the 3.0 mg/kg dose group and 67% in the 4.5 mg/kg dose group.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

<a id="topic-3.1.5.8.3-12"></a>

##### Week 24 maintenance of a Week 12 complete response (UAS7 = 0), doses of 1.5 mg/kg or more

> “During post-treatment follow up, 71% (10 of 14) of patients who had been treated with doses greater than or equal to 1.5 mg/kg and had a complete response (UAS7=0) at Week 12, remained urticaria free at Week 24 (patients received last dose of barzolvolimab at Week 8).”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-3.1.5.8.3-13"></a>

##### Interim Week 8 and Week 12 UAS7 and UCT results, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in all patients in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in all patients in the 3.0 mg/kg dose group (n=9) at week 8 (reflects one dose; ongoing), demonstrating clinically meaningful symptom improvements for patients.”
> “Complete response (UAS7=0) of 57.1% in the 1.5 mg/kg dose group at week 12 and 44.4% at week 8 (reflects one dose; ongoing) in the 3 mg/kg dose group which is a key therapeutic goal.”
> “75% well-controlled disease by Urticaria Control Test (UCT) in the 1.5 mg/kg dose group at week 12 and 83.3% in the 3 mg/kg dose group at week 8 (reflects one dose; ongoing).”
> “As predicted, the lowest dose of 0.5 mg/kg resulted in suboptimal clinical activity compared to the higher doses.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.8.3-14"></a>

##### Angioedema: AAS7 improvement and angioedema-free participants (AAS7 = 0) at Weeks 12 and 24

> “The AAS7 results demonstrated rapid, durable symptom improvement in angioedema in the barzolvolimab groups (Figure S5).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “31 patients on study (n=26 barzolvolimab; 5=placebo) reported angioedema activity at baseline when enrolling in the study. 86% of the barzolvolimab treated patients at 1.5 mg/kg or greater were angioedema free at week 12 and 83% were angioedema free at week 24.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

> “Angioedema free patients* at doses ≥ 1.5 mg/kg:”
> “Angioedema free AAS7* = 0”
> “Only patients who reported angioedema activity at baseline”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-15"></a>

##### Physician Global Assessment (PhysGA) from Week 1 through Week 24

> “Physician Global Assessment (PhysGA) showed decreases starting at Week 1 (mean baseline score for pooled barzolvolimab group = 2.2 vs. 0.6 [Week 1]), which were sustained through Week 24 (Week 24 = 0.8 [1.5 mg/kg], 0.4 [3.0 mg/kg], and 0.6 [4.5 mg/kg]; Figure S6B).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-16"></a>

##### Pharmacokinetics: exposure through 24 weeks and dose-linear Cmax and AUC

> “Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A). Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1). Increased clearance and lower volumes of distribution were observed in patients who received lower doses.”
> “Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-17"></a>

##### Pharmacodynamics: serum tryptase suppression and plasma SCF increase

> “Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B). Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation. Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### DLQI through Week 24 at doses of 1.5 mg/kg or more

> “Decreases in the Dermatology Life Quality Index (DLQI) mean scores for the ≥ 1.5‐mg/kg barzolvolimab groups were sustained through Week 24 (baseline score = 11.3 in pooled barzolvolimab group vs. Week 24 mean scores = 1.3 [1.5 mg/kg], 3.2 [3.0 mg/kg], and 2.0 [4.5 mg/kg]; Figure S6A).”
> “The increased symptom control observed with barzolvolimab was reflected in the quality of life measurements, which showed profound improvement between Weeks 1 and 4 that was sustained through Week 24.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.4-2"></a>

##### DLQI decrease within 4 weeks in all barzolvolimab groups

> “A rapid decrease in the DLQI was noted within 4 weeks in all barzolvolimab treated patients.”
> “DLQI improvement was sustained at doses ≥1.5 mg/kg.”
> “DLQI and PhysGA trended closely with the dose-dependent improvement in UAS7 and UCT, tryptase suppression, and increases in SCF.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events through 24 weeks: incidence, infusion-related events, interruptions, and discontinuations

> “Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.”
> “Most AEs were mild or moderate in severity and resolved while on study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-2"></a>

##### TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks

| TEAE, n (%) | 0.5 mg/kg Q4W (N = 9) | 1.5 mg/kg Q4W (N = 8) | 3.0 mg/kg Q8W (N = 9) | 4.5 mg/kg Q8W (N = 9) | All barzolvolimab (N = 35) | Pooled placebo (N = 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Any TEAE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “6 (60)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Leukopenia | “1 (11)” | “1 (13)” | “1 (11)” | “0 (0)” | “3 (9)” | “0 (0)” |
| Diarrhea | “1 (11)” | “0 (0)” | “1 (11)” | “1 (11)” | “3 (9)” | “0 (0)” |
| Fatigue | “1 (11)” | “1 (13)” | “0 (0)” | “1 (11)” | “3 (9)” | “1 (10)” |
| Infections and infestations | “1 (11)” | “4 (50)” | “5 (56)” | “4 (44)” | “14 (40)” | “2 (20)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Nasopharyngitis | “0 (0)” | “1 (13)” | “2 (22)” | “1 (11)” | “4 (11)” | “1 (10)” |
| Urinary tract infection | “1 (11)” | “2 (25)” | “1 (11)” | “0 (0)” | “4 (11)” | “0 (0)” |
| Arthralgia | “2 (22)” | “0 (0)” | “0 (0)” | “1 (11)” | “3 (9)” | “0 (0)” |
| Back pain | “0 (0)” | “1 (13)” | “2 (22)” | “0 (0)” | “3 (9)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1 (11)” | “5 (14)” | “2 (20)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “5 (56)” | “9 (26)” | “0 (0)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-3"></a>

##### Hair color changes: locations and resolution

> “Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-4"></a>

##### Taste changes

> “Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-5"></a>

##### Infections and their relation to neutrophil decreases

> “A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-6"></a>

##### Serious adverse event: grade 4 salmonella gastroenteritis assessed as unrelated

> “One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-7"></a>

##### Hematologic decreases after the first dose and grade 3 shifts

> “Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-8"></a>

##### Immunogenicity: antidrug antibodies in 57% without apparent effect on exposure or safety

> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-9"></a>

##### Immunogenicity: antidrug antibodies in 51%, November 2022 data cutoff

> “Data cut 29NOV2022”
> “Treatment-emergent ADA observed in 51% of patients receiving study drug, without apparent impact on exposure.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.5-10"></a>

##### KIT-mediated adverse events and expected recovery after drug clearance

> “The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition. The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections.”
> “All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-11"></a>

##### Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff

> “Data cut 29NOV2022”
> “Includes preferred terms: urinary tract infection, cystitis, and bacteriuria”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Any AE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “5 (50)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “4 (44)” | “8 (23)” | “0 (0)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1(11)” | “5 (14)” | “1 (10)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “2 (25)” | “2 (22)” | “0 (0)” | “5 (14)” | “0 (0)” |

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.5-12"></a>

##### Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster

> “Includes preferred terms: urinary tract infection, cystitis, and bacteriuria.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “3 (38)” | “3 (33)” | “0 (0)” | “7 (20)” | “0 (0)” |

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.8.5-13"></a>

##### Interim safety, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “Most AEs were mild or moderate in severity and resolved while on study, with none leading to treatment discontinuation. The most common treatment emergent adverse events were urinary tract infections, headache, neutropenia and back pain. UTIs, headache and backpain were all reported as unrelated to treatment.”
> “Four patients with screening and baseline neutrophil counts at the lower end of the normal range on study initiation had decreases in neutrophil counts reported as AEs.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.8.5-14"></a>

##### Neutrophil decreases reported as adverse events and hematologic recovery, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Changes in hematologic parameters were consistent with observations in single dose studies, with no pattern of further decreases with multiple doses; hematologic values generally remained within the normal range and returned to baseline levels during the follow up period. Five patients had decreases in neutrophil counts reported as AEs; four of which were previously reported in the EAACI 2022 data presentation.”
> “UTIs and COVID-19 were reported as unrelated to treatment.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

- Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
- Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
- Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
- Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
- Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
- Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
- Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
- Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
- Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
- Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
- Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
- Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
- The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
- Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
- External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/); [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794); [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0); [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data); [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf); [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf); [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
